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IMPROVING TRAUMA CARE WORLDWIDE
Tranexamic acid in trauma: we need stronger global
health policy
Tranexamic acid substantially reduces death in bleeding trauma patients. So why are the World
Health Organization, the United Nations, the World Bank, and Unicef not ensuring global
implementation, ask Ian Roberts and colleagues
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Youmight expect that the identification of a highly cost effective
treatment for a disease that kills more people each year than
HIV/AIDS, malaria, and tuberculosis combined would stimulate
an immediate global health policy response, with strong efforts
to make the treatment freely available to all those who need it.1
Knowing that the United Nations General Assembly had
proclaimed 2011-20 to be a “decade of action” for tackling this
particular health scourge, you might feel sure that concerted
action was being taken.2 You would be wrong. The “disease”
is trauma, and the treatment is a short infusion of a generic drug
called tranexamic acid, but there has been no global health
policy response.3-6
In 2010 a collaboration of doctors and nurses from 40 countries
reported that tranexamic acid safely reduces mortality in
bleeding trauma patients. Given within three hours of injury, it
reduced the risk of bleeding to death by one third, with no
discernible side effects.4 Economic analysis shows that
tranexamic acid in trauma is among the most cost effective ways
available to save a life—more cost effective than antiretroviral
treatment for HIV and nearly as cost effective as bed nets for
malaria prevention.5 If all patients admitted to hospital with
traumatic bleeding worldwide received tranexamic acid within
three hours, there would be at least 100 000 fewer trauma deaths
a year.7
Within weeks of publication of these findings, the British army
was using tranexamic acid on the battlefield, and two years later
it has been widely implemented throughout the NHS, having
been included in the guidelines of the Joint Royal Colleges
Ambulance Liaison Committee for prehospital practice and in
the Department of Health’s best practice for trauma.8 The trial
investigators successfully applied to get tranexamic acid
included in the World Health Organization’s list of essential
medicines, but implementation efforts by organisations from
which we would expect health policy leadership—WHO, the
UN, World Bank, and Unicef—have been limp or absent.
It seems that some deaths are more important than others. In
2011 more than eight million people with HIV infection in low
and middle income countries received antiretroviral treatment.9
This is appropriately considered one of the most important
global health achievements of the past decade and is all the more
remarkable because diagnosis of HIV infection requires a
laboratory test and the patient must be treated for life. But if
such patients arrive at the emergency department with major
trauma (and about a quarter of trauma patients in sub-Saharan
Africa are HIV positive) they might die for want of a short
infusion of a drug that costs a fraction of the cost of a unit of
blood.10
Wider use of tranexamic acid in surgery would save blood. A
systematic review of randomised trials showed that tranexamic
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acid reduced the number of patients receiving a blood
transfusion by a third.11Reducing use of blood in surgery would
make more available for situations where transfusion might be
life saving, such as in children with malaria or mothers with
postpartum bleeding.
And tranexamic acid is safer than blood. The risks of becoming
infected with HIV, hepatitis B virus, or hepatitis C from a blood
transfusion in sub-Saharan Africa are estimated at 1, 4.3, and
2.5 infections per 1000 units, respectively.12 If annual transfusion
requirements projected by WHO were met, blood transfusions
alone would be responsible for 28 595 hepatitis B infections,
16 625 hepatitis C infections, and 6650 HIV infections every
year. Because it reduces the need for transfusion, tranexamic
acid is a cost effective way to reduce viral infections transmitted
by transfusion.13
Recognising these opportunities requires a new mode of
thinking. It requires a move away from disease based leadership,
where tribal leaders bang the drum of disease burden in search
of the funds to prevent the specific illness that interests them
most, towards people centred care, aimed at achieving the best
health given the available resources.
The CRASH-2 trial was funded by UK taxpayers, and UK
taxpayers have been the first to benefit. However, the trial was
possible only because hundreds of doctors and nurses in 40
countries worked together in the interests of patients everywhere
to recruit the 20 211 patients, 3076 of whom died. The trial
turned private tragedy into a public good, and this must now be
used to inform global policy.
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